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Abstract
Introduction To understand which signalling pathways become
deregulated in breast cancer, it is necessary to identify
functionally significant gene expression patterns in the stem,
progenitor, transit amplifying and differentiated cells of the
mammary epithelium. We have previously used the markers
33A10, CD24 and Sca-1 to identify mouse mammary epithelial
cell subpopulations. We now investigate the relationship
between cells expressing these markers and use gene
expression microarray analysis to identify genes differentially
expressed in the cell populations.
Methods Freshly isolated primary mouse mammary epithelial
cells were separated on the basis of staining with the 33A10
antibody and an α-Sca-1 antibody. The populations identified
were profiled using gene expression microarray analysis. Gene
expression patterns were confirmed on normal mouse and
human mammary epithelial subpopulations and were examined
in a panel of breast cancer samples and cell lines.
Results Analysis of the separated populations demonstrated
that Sca-1- 33A10High stained cells were estrogen receptor α
(Esr1)- luminal epithelial cells, whereas Sca-1+ 33A10Low/-
stained cells were a mix of nonepithelial cells and Esr1+
epithelial cells. Analysis of the gene expression data identified
the gene Rgs2 (regulator of G-protein signalling 2) as being
highly expressed in the Sca-1- 33A10Low/- population, which
included myoepithelial/basal cells. RGS2 has previously been
described as a regulator of angiotensin II receptor signalling.
Gene expression analysis by quantitative real-time RT-PCR of
cells separated on the basis of CD24 and Sca-1 expression
confirmed that Rgs2 was more highly expressed in mouse
myoepithelial/basal mammary cells than luminal cells. This
expression pattern was conserved in normal human breast cells.
Functional analysis demonstrated RGS2 to be a modulator of
oxytocin receptor signalling. The potential significance of RGS2
expression in breast cancer was demonstrated by semi-
quantitative RT-PCR analysis, data mining and quantitative real-
time RT-PCR approaches, which showed that RGS2 was
expressed in the majority of solid breast cancers at much higher
levels than in normal human mammary cells.
Conclusion Molecular analysis of prospectively isolated
mammary epithelial cells identified RGS2 as a modulator of
oxytocin receptor signalling, which is highly expressed in the
myoepithelial cells. The RGS2 gene, but not the oxytocin
receptor, was also shown to be over-expressed in the majority of
breast cancers, identifying the product of this gene, or the
pathway(s) it regulates, as potentially significant therapeutic
targets.Page 1 of 16
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Signal transduction pathways are commonly dysregulated in
breast cancer. Estrogen receptor signalling is the best charac-
terised aberrant signalling pathway in the disease [1], but
others include the human epidermal growth factor receptor
(HER)2, epidermal growth factor receptor (EGFR), prolactin
receptor and oxytocin receptor pathways [2-7]. A striking fea-
ture of these receptors and their downstream pathways is that
they are important determinants of the growth, development
and function of the normal breast epithelium [3,4,8,9]. It is
likely that the competence of mammary epithelial cells to
respond to these signalling pathways in normal development
leads to selective pressure to recruit these molecules into the
process of tumourigenesis. Understanding the molecular
mechanisms that underlie normal cell growth and functional
differentiation in the normal mammary gland is therefore critical
to developing new therapeutic approaches that target these
signalling pathways. A key step in developing such an under-
standing must be knowledge of genes expressed in the differ-
ent cellular compartments of the mammary epithelium and
their relationship to the function(s) of that compartment.
The adult mouse mammary epithelium consists of a network of
ducts together with (in the pregnant/lactating gland) milk-pro-
ducing alveoli, the latter being equivalent to the terminal ductal
lobulo-alveolar units in human [10]. Both of these structures
consist of two basic cell layers: an inner luminal epithelial layer
and an outer basal epithelial layer. Luminal cells line the ducts,
form the differentiated milk-secreting cells in the alveoli, and
are the principal target for estrogen and prolactin. The basal
layer is mainly composed of myoepithelial cells, which contract
in response to oxytocin released during lactation to force milk
from the alveoli down the ducts to the nipple. The basal cell
layer also contains the stem cell compartment, which main-
tains the epithelium [11-14].
We have previously used a variety of cell surface markers to
isolate and characterize these populations. These have
included a mouse luminal epithelial milk fat globule membrane
antigen (recognized by the 33A10 antibody [15,16]) to isolate
mouse mammary luminal epithelial cells [17,18]; CD24 to iso-
late both basal/myoepithelial and luminal epithelial cells
[12,14]; and Sca-1 and Prominin-1 (the mouse homologue of
CD133), which both recognize estrogen receptor-α positive
(Esr1+) luminal epithelial cells [14]. We have shown that the
basal epithelial compartment is enriched for epithelial stem cell
activity [12,14] and confirmed that this activity can be further
purified on the basis of high CD49f expression [13,14]. In our
previous studies, however, we confined molecular analysis of
these populations to characterizing their function on the basis
of expression of genes with known or predicted cell-type spe-
cific distributions.
The aim of the present study, therefore, was to identify genes
that have not previously been characterized as being differen-
tially expressed in mammary epithelial cell populations, with
particular focus on genes with dysregulated expression in
breast cancer. As a result of this analysis we have identified
the G-protein coupled receptor (GPCR) regulator RGS2
(which encodes the regulator of G-protein signalling 2
[RGS2]) as being differentially expressed in the various breast
epithelial populations. Furthermore, this gene is over-
expressed in the majority of breast cancers, making it a poten-
tial new target for the development of therapeutics.
Materials and methods
Antibodies
Anti-mouse Sca-1-PE antibody (clone D7; used at 0.1 μg/ml),
mouse adsorbed anti-rat IgG-FITC (used at 1 μg/ml) and non-
specific rat IgG control antibodies were obtained from South-
ern Biotechnology (Cambridge Bioscience, Cambridge, UK).
33A10 rat IgG antibody supernatant (used undiluted) was a
kind gift from Professor A Sonnenberg (Netherlands Cancer
Institute, Amsterdam, The Netherlands). Rat anti-mouse
CD45-PE-Cy5 and CD45-PE-Cy7 (clone 30-F11; used at
0.25 μg/ml) and anti-CD24-FITC (clone M1/69; used at 0.5
μg/mL) were obtained from BD Biosciences (Oxford, UK).
Anti-CD24-PE-Cy5 (clone M1/69; used at 0.25 μg/ml) was
obtained from Insight Biotechnology (London, UK).
Plasmids
The RGS2 coding sequence without 5' or 3' untranslated regions
was isolated from an IMAGE clone (3681138; Geneservice,
Cambridge, UK) in pDNR-LIB by PCR using the primers 5'-
GGCTCGAGGCCGCCACCATGCAAAGTGCTATGTCTTG-3'
and 5'-GGCTCGAGTCATGTAGCATGAGGCTC-3'. These
primers added a Kozak consensus sequence to the 5' end and
XhoI restriction enzyme recognition sites to both ends of the
amplified sequence. The PCR product was cloned using the
pCR-TOPO-XL kit (Invitrogen, Paisley, UK) and then sub-
cloned from this vector into pcDNA3.1- (Invitrogen) by XhoI
digest. HindIII restriction digests indicated plasmids with the
RGS2 sequence in the correct orientation (shown by excision
of a 510 base pair fragment). Plasmids with the RGS2 insert
in the correct orientation were sequence verified.
Preparation and flow cytometric separation of single 
mammary cell suspensions
Mammary epithelial organoids were harvested from fourth
mammary fat pads of virgin female FVB mice aged 10 to 12
weeks and processed to single cells as previously described
[12]. For anti-Sca-1/33A10/anti-CD24 sorting, cell suspen-
sions (at 106 cells/ml) were stained as detailed in Table 1.
Staining and sorting with anti-CD24-FITC and anti-Sca-1-PE
for isolation of mouse mammary basal/myoepithelial, Esr1+
luminal and Esr1- luminal cells was carried out as described
previously [14]. Analysis and exclusion of dead cells, CD45+
cells and nonsingle cells was carried out as described previ-
ously [12]. Nonspecific IgG controls were used for compensa-Page 2 of 16
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using FlowJo [19].
Cell culture
Hs578T cells (Sigma, Poole, Dorset, UK) were cultured in Dul-
becco's modified Eagle's medium (Invitrogen) with 10% (vol/
vol) foetal calf serum (FCS; PAA Laboratories, Somerset, UK)
and 10 μg/mL insulin (Sigma). Primary mouse fibroblasts iso-
lated during the preplating procedure in the mammary cell har-
vest were cultured in Dulbecco's modified Eagle's medium/
10% (vol/vol) FCS for up to 2 weeks before RNA isolation.
cDNA microarray gene expression analysis on freshly 
isolated mammary epithelial cells
Cells were freshly isolated from mammary tissue, with no inter-
vening culture period, and sorted into sterile screw-cap
eppendorf tubes. After sorting, cells were pelleted by spinning
in a benchtop centrifuge at 700 g for 5 minutes. Phosphate-
buffered saline (PBS) supernatant was aspirated and cell pel-
lets resuspended in 800 μl Trizol reagent (Invitrogen). Where
necessary, multiple pellets of the same population were
pooled in the 800 μl volume. Cultures of primary mouse mam-
mary fibroblasts were washed in PBS and then scraped into
Trizol. Samples were stored at -80°C until required for RNA
extraction. Total RNA was extracted according to the manu-
facturers' instructions from two independent Sca-1+
33A10Low/- samples, two independent Sca-1- 33A10Low/- sam-
ples, three independent Sca-1- 33A10High samples, and four
independent mammary fibroblast samples. Quality and quan-
tity of the total RNA was assessed using an RNA 6000 nano
chip on the Agilent Bioanalyzer (Agilent Technologies UK Lim-
ited, Stockport, Cheshire, UK). One hundred nanograms of
total RNA was amplified using the AminoAllyl MessageAmp
aRNA kit (Ambion, Huntingdon, UK), in accordance with the
manufacturer's protocol.
Reference RNA was generated from a pool of RNAs extracted
from three mammary cell preparations harvested and sorted to
exclude CD45+ cells only. This total RNA pool was amplified
using the same technique. Five micrograms of amino allyl
aRNA from both test and reference RNA were coupled with
either Cy3 or Cy5 fluorochromes (GE Healthcare, Bucking-
hamshire, UK) and purified with an AminoAllyl MessageAmp
aRNA kit (Ambion).
Dye-labelled test and reference aRNA were co-hybridised on
to an in-house (Breakthrough Breast Cancer Centre) cDNA
mouse microarray containing 13,825 features (NIA 15K
Mouse cDNA clone set) [20,21]. Slides were incubated in a
42°C hybridization oven for 16 hours. Washes performed
once in 2× sodium chloride/citrate (SSC) and 0.1% (w/v)
SDS for 15 minutes, followed by three washes in 0.1 × SSC
and 0.1% (weight/vol) SDS for 10 minutes each, and two final
washes in 0.1 × SSC for 2 minutes each time. All washes
were performed at 65°C. Slides were spin dried before
scanning.
Microarray data analysis
Each hybridization was performed in duplicate as a dye swap
hybridization. Slides were scanned using an Axon 4000B
scanner (Axon Instruments, Burlingame, CA, USA) and images
were analysed using Genepix Pro 5.1 software (Axon Instru-
ments). Aberrant or distorted spots were removed from analy-
sis. Expression measurements were obtained after log2
Table 1




First incubation Second incubation Third incubation
Nonspecific staining control Rat immunoglobulin α-rat-FITC IgG-PE IgG-PE-Cy5 2IgG-PE-Cy7 No
ToPRO-3 or DAPI control None N/A N/A Yes
33A10 control 33A10 Anti-rat-FITC N/A No
Sca-1 control α-Sca-1-PE N/A N/A No
CD45 control aα-CD45-PE-Cy5 or bα-CD45-PE-Cy7 N/A N/A No
bCD24 control bα-CD24-PE-Cy5 N/A N/A No
Experimental sample 33A10 α-rat-FITC α-Sca-1-PE aα-CD45-PE-Cy5 or bα-
CD45-PE-Cy7 bα-CD24-PE-Cy5 Yes
aAnti-CD45-PE-Cy5 was used for the four-colour protocol not including CD24. bAnti-CD45-PE-Cy7, anti-CD24-PE-Cy5 and the IgG-PE-Cy7 
isotype control were only used in the five-colour protocol including CD24 detection. 'Fluorescence minus one (FMO)' controls based on the 
staining combination used for the experimental sample but in which one antibody was left out and replaced with its isotype control were also used 
to set sort gates correctly. For simplicity, these have not been shown. Live/Dead cell exclusion used either ToPRO-3 or DAPI (4,6-diamidino-2-
phenylindole dihydrochloride).Page 3 of 16
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zation within each array [22]. Differential gene expression was
determined by using the limma package [23] in the R 2.1.1
environment [24] and BioConductor 1.6 [25]. Differentially
expressed genes were ranked according to their P value and
M ratio, and genes with a false discovery predication of P value
< 0.05 were included for further studies [26]. A full list of sig-
nificantly over-expressed and under-expressed annotated
genes from the four populations is given in Additional files 1 to
4. A combined list of all the genes from Additional files 1 to 4,
allowing comparisons of the P values across the populations,
is given in Additional file 5. The complete datasets, together
with unpublished analyses, have been submitted according to
MIAME (Minimum Information About a Microarray Experiment)
guidelines [27] to the public data repository ArrayExpress [28]
with accession number E-MEXP-423.
Data mining
The gene expression data from normal luminal epithelial cells,
myoepithelial cells and epithelial enriched primary breast can-
cers were obtained from the reported study by Grigoriadis and
coworkers [29]. The expression pattern for human RGS2 was
extracted using the Unigene ID Hs.78944 as an identifier.
Semi-quantitative RT-PCR analysis of cell lines and 
breast tumour samples
Total RNA (10 μg) from primary samples and cell lines derived
from both normal breast and breast cancers was used for each
40 μl reverse transcription reaction. Samples included the fol-
lowing: a normal, immortalized but nontransformed human
myoepithelial cell line 1089M (derived from primary myoepi-
thelial cells purified from human reduction mammoplasty tis-
sue and immortalized with SV40 large T-antigen and hTERT,
and then subjected to a second round of myoepithelial specific
purification; a kind gift from Dr Mike Allen, Queen Mary's
School of Medicine and Dentistry, London); a pool of RNA
from 10 freshly isolated primary breast luminal epithelial cell
samples [29]; immortalized but nontransformed human luminal
cell lines 1089L, HB4A [30], 226L33, 226L39 (normal human
breast luminal cells immortalized with temperature-sensitive
SV40 large T-antigen; a kind gift from Professor Parmjit Jat,
Ludwig Institute for Cancer Research) and HBL100 [31]; nor-
mal human breast derived endothelial cells and fibroblasts
[32]; a panel of ESR1+, ERBB2+, myoepithelial origin and non-
estrogen responsive cell lines [33]; and 56 primary breast can-
cers, of which 20 had been purified to remove F19 antigen-
expressing desmoplastic fibroblasts (termed F19- breast can-
cers) [29]. Unless otherwise stated, samples were a kind gift
of Professor Mike O'Hare, Ludwig Institute for Cancer
Research. To determine the expression in this panel of RGS2,
OXTR (encoding oxytocin receptor) and a control house keep-
ing gene B2M (encoding β2-microglobulin), 10 μl of 1/50
diluted cDNA was used per 30 μl RT-PCR with primers for
RGS2 (5'-CGAGGAGAAGCGAGAAAAGA-3' and 5'-TTC-
CTCAGGAGAAGGCTTGA-3'), OXTR (5'-TTCTTCGTGCA-
GATGTGGAG-3' and 5'-GGACGAGTTGCTCTTTTTGC-3'),
or B2M (5'-ACTCTGCTTAGAATTTGGGG-3' and 5'-
CCACAACCATGCCTTACTTT-3'). Absence of contaminat-
ing genomic DNA was confirmed by analysis of samples in an
Agilent Bioanalyser. The RGS2 and OXTR primers were
designed such that they spanned one or more intron-exon
boundaries and would give bands of the expected size (150
base pairs for RGS2 and 233 base pairs for OXTR) only when
amplifying from cDNA not from genomic DNA.
RT-PCR was performed by using the Applied Biosystems
AmpliTaq Gold (Applied Biosystems, Warrington, UK), with
32 (RGS2), 36 (OXTR) or 25 (B2M) cycles each consisting of
30 seconds at 94°C, 30 seconds at 60°C, and 45 seconds at
72°C. PCR products were visualized on 2% (weight/vol) aga-
rose E-Gels 96 Gels (Invitrogen). An IMAGE clone of RGS2
(3681138) and cDNA made from RNA isolated from Hs578T
cells, which express a functional oxytocin receptor [34], were
used as positive controls for the RGS2 and OXTR PCRs,
respectively.
Quantitative PCR analysis
Quantitative real time PCR (qPCR) reactions were carried out
as described previously [14] to determine fold changes in
expression of Esr1 (estrogen receptor-α) and Prlr (prolactin
receptor) [14] in mammary epithelial cell subpopulations com-
pared with a leucocyte-depleted, bulk mammary cell (CD45-)
comparator sample. For qPCR assays on mouse Rgs2 (Uni-
gene ID Mm.28262; Taqman Assays on Demand reference
Mm00501385_m1) or human RGS2 (Unigene ID Hs. 78944;
Taqman Assays on Demand reference Hs00180054_m1),
fold changes in expression were compared with mouse or
human mammary fibroblasts. In all cases, GAPDH (Taqman
Assays on Demand reference for mouse Mm99999915_g1,
for human Hs00266705_g1) was used as an internal control.
Data were expressed as mean fold changes across samples
together with 95% confidence intervals. Significance was
determined by comparing confidence interval overlaps [35].
Analysis of normal primary human cells was carried out on two
pools of RNA from freshly isolated normal myoepithelial cells
and two pools of RNA from freshly isolated normal luminal
cells (a kind gift of Professor Mike O'Hare). Each cell pool was
derived from at least 10 separate isolates of normal primary
human breast cells. Each of the myoepithelial pools was ana-
lyzed in duplicate, using two separate cDNA syntheses. One
luminal pool was analysed in duplicate and one in triplicate
with separate cDNA syntheses. Analysis of cell lines and
tumour samples was carried out on a selection of the samples
described above.
Transfections
For small interfering (si)RNA analysis, Hs578T cells were
seeded at 1.4 × 105 cells per well in six-well plates (Falcon;
BD Biosciences) in antibiotic-free medium. The following day,Page 4 of 16
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siRNA (D-001210-01; Dharmacon, Perbio Science Belgium,
Erembodegem, Belgium) or an siRNA targeting human RGS2
(Hs_RGS2_1_HP siRNA; Qiagen, Crawley, West Sussex,
UK; siRGS2) using Lipofectamine reagent (Invitrogen), in
accordance with the manufacturer's instructions. The
response of the cells to oxytocin stimulation (see below) was
measured 48 hours later. As a transfection control, additional
cells were transfected with an siRNA targeting the PLK1
(polo-like kinase 1) gene (hs_PLK1_6_HP; Qiagen), which is
lethal (Lord C, Ashworth A, unpublished data). To confirm
gene silencing, qPCR analysis of RGS2 expression levels in
siCON versus siRGS2 transfected wells was carried out.
To establish cell lines stably over-expressing RGS2, Hs578T
cells were transfected with PvuI-linearized pcDNA3.1-RGS2,
empty pcDNA3.1- or mock transfected, using Lipofectamine
2000 (Invitrogen), in accordance with the manufacturer's
instructions. After 48 hours, cells were selected with 0.5 mg/
ml Genetecin (Invitrogen), sufficient to select completely
against nontransfected cells. The mock transfected cells all
died, but multiple colonies survived in the transfected cultures.
The cell lines were maintained as polyclonal populations,
under Genetecin selection, to minimize potential variation due
to plasmid integration effects.
Oxytocin receptor activity assays
To assess oxytocin receptor signalling to the downstream
p44/42 mitogen-activated protein kinase (MAPK) pathway
[36], control and transfected cells in six-well plates were
serum and insulin starved for 2 hours and then stimulated with
either 1 × 10-7 mol/l (RGS2 silencing) or 5 × 10-7 mol/l (RGS2
over-expression) oxytocin (Sigma) for varying times up to 2
hours. At each time point, medium was removed, the cells
were washed with cold PBS and then scraped into 0.5 ml cold
lysis buffer (50 mmol/l Tris [pH 7.4], 5 mmol/l EDTA, 150
mmol/l NaCl, 1% Igepal, 2 mmol/l DTT, 1:100 protease inhib-
itor cocktail, 1:100 phosphatase inhibitor cocktail 1, and
1:100 phosphatase inhibitor cocktail 2; all reagents from
Sigma). Samples were lysed on ice for 20 minutes and then
spun at 25000 g in a benchtop centrifuge for 10 minutes at
4°C. Pelleted insoluble material was discarded and Bradford
protein assays carried out on the supernatants. Supernatant
samples were mixed with 2 × SDS loading buffer and ana-
lysed by SDS-PAGE on 10% polyacrylamide gels and West-
ern blotting. Sample loading was normalised using the results
of the Bradford assays. Blots were probed with antibodies
against Phospho-p44/42 MAPK (Thr202/Tyr204; #9101;
Cell Signalling Technology, NEB, Hitchin, Herts, UK) and total
p44/42 MAPK (#9102; Cell Signalling Technology), in
accordance with the manufacturer's instructions. A Typhoon
Phosphoimager (GE Healthcare, Buckinghamshire, UK) was
used to quantify the intensity of the phosphorylated and total
bands. The ratios of the corresponding bands was determined
and then the percentage of p44/42 phosphorylation at each
timepoint was compared with time 0 (0 minutes). Statistical
analysis on the p44/42 phosphorylation levels was carried out
using a χ2 method, testing whether the observed level of phos-
phorylation in the Hs578T-RGS2 cells or siRNA transfected
cells treated with oxytocin differed significantly from the
expected level of phosphorylation (in the control samples
treated with oxytocin) across the timepoints.
To assess oxytocin signalling-mediated elevation of intracellu-
lar calcium levels, a calcium flux assay based on the Fluo-3/
Fura Red system was used [37]. In brief, cells were trypsinized
and re-suspended at 5 × 105/ml in room temperature phenol-
red-free Leibowitz L15 medium/10% (vol/vol) FCS plus 0.1
mmol/l sulfinpyrazone (Sigma). Fluo-3-AM and Fura Red-AM
(Invitrogen) were then added to final concentrations of 1 and
2 μmol/l, respectively. Cells were incubated at room tempera-
ture for 30 minutes then washed and resuspended in room
temperature phenol-red-free L15/10% FCS plus 0.1 mmol/l
sulfinpyrazone plus 1:10,000 DAPI (4,6-diamidino-2-phenylin-
dole dihydrochloride). After a further 30 minutes at room tem-
perature the samples were analyzed on a Becton Dickenson
LSRII flow cytometric analyser (Becton Dickenson, Oxford,
UK). Dead cells and doublets were gated out of the analysis,
as described previously [12], and the ratio of Fluo-3/Fura Red
fluorescence was plotted against time. This ratio increases
with increasing [Ca2+]i. The fluorescence ratio for each sample
was analysed using FlowJo for 60 seconds before addition of
5 × 10-7 mol/l oxytocin, to obtain a baseline value, and then for
150 seconds afterward. To compare samples, mean fluores-
cence ratios for the baseline readings and for 25 second inter-
vals after stimulus addition were plotted.
Ethical approval
Harvest of animal tissue for cell separation was carried out
under Schedule 1 of the 1986 Animals (Scientific Procedures)
Act. Informed consent to use human material for scientific
research was obtained.
Results
33A10 and α-Sca-1 staining identifies mammary cell 
populations with distinct gene expression patterns
We previously characterized the antibody 33A10 as an exclu-
sive marker of mouse mammary epithelial luminal cells [17,18]
and have demonstrated that Sca-1 expression is a marker of
estrogen receptor-α expressing cells within the luminal epithe-
lial compartment [14]. Therefore, to isolate mammary luminal
epithelial cell subpopulations for gene expression analysis,
freshly harvested primary mammary cell suspensions were
stained with 33A10, anti-Sca-1 and anti-CD45 antibodies,
and separated by flow cytometry. Dead cells and CD45+ cells
were excluded from the analysis. A typical flow cytometry pro-
file is shown in Figure 1a. Three main cell populations were
identified: Sca-1+ 33A10Low/- (14.7 ± 4.8%), Sca-1-
33A10High (44.3 ± 8.0%) and Sca-1- 33A10Low/- (25.4 ±
6.3%; n = 5 independent sorts). Surprisingly, given thatPage 5 of 16
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Esr1+ luminal epithelial cells, no substantial Sca-1+ 33A10High
population was observed.
Isolated Sca-1+ 33A10Low/-, Sca-1- 33A10High and Sca-1-
33A10Low/- cells were used to generate gene expression pro-
files for each of these subpopulations, compared with a refer-
ence sample consisting of pooled bulk mammary CD45- cell
preparations. In addition, gene expression patterns in mam-
mary fibroblasts, isolated by differential plating during the cell
preparation procedure, were also compared with the same ref-
erence sample. Additional files 1 to 4 list the well annotated
differentially expressed genes significantly increased and
decreased in the four populations compared with bulk CD45+-
depleted mammary cells according to limma (false discovery
rate method) analysis. Additional file 5 compares gene expres-
sion in all four populations.
To understand the relationship between the four cell popula-
tions, principal component analysis was carried out on the four
datasets (Figure 1b). This analysis showed that the Sca-1-
33A10High and fibroblast populations were most distinct,
whereas the Sca-1+ 33A10Low/- and the Sca-1- 33A10Low/-
populations had the greatest similarity. However, none of the
populations clustered together, confirming that the flow
cytometric separation did indeed isolate three largely separate
populations, which themselves are all different to the mammary
fibroblasts.
To confirm that the Sca-1+ 33A10Low/- population included the
Sca-1+ hormone receptor-expressing luminal epithelial cells
that we previously identified [14], qPCR for the prolactin
receptor and estrogen receptor-α (Prlr and Esr1) was carried
out on Sca-1+ 33A10Low/- and Sca-1- 33A10High cells. The
results (Figure 1c) demonstrated that Sca-1+ 33A10Low/- cells
were indeed enriched for Prlr and Esr1 expression, whereas
Figure 1
Isolation and characterisation of mammary epithelial cell subpopulations. (a) Flow cytometric staining profiles (dead and CD45+ cells excluded) of 
anti-Sca-1 and 33A10 stained, freshly isolated mouse mammary cell preparations together with nonspecific IgG-stained control. (b) Graphical 
space representation of principal component analysis of mammary fibroblasts, Sca-1+ 33A10Low/-, Sca-1- 33A10High and Sca-1- 33A10Low/- cells. (c) 
Mean fold differences ± 95% confidence limits in RNA abundance measured by quantitative real-time PCR for estrogen receptor (Esr1) and prolac-
tin receptor (Prlr) transcripts in Sca-1+33A10Low/- (n = 5 samples) and Sca-1- 33A10High (n = 3 samples) mammary subpopulations compared with 
bulk mammary cell preparations depleted for CD45+ cells (comparator; n = 3 samples). The dotted lines indicate the 95% confidence limits of the 
comparator sample. All samples show a significant difference to the comparator (**P < 0.01) [35].Page 6 of 16
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/9/6/R85Sca-1- 33A10High luminal epithelial cells were depleted for
expression of these genes.
To characterize the biological processes that may be occur-
ring within each cell type, and therefore to better understand
their function, Gene Ontology analysis of the biological proc-
esses to which each enriched gene contributes was carried
out (Additional file 6). This analysis showed that significant
processes elevated in Sca-1- 33A10High cells involved ion and
lipid metabolism and transport processes. This was not unex-
pected for cells of the luminal mammary epithelium. Interest-
ingly, however, phagocytosis was also found to be an
important biological process in this cell population. The Sca-1-
33A10Low/- cells, Sca-1+ 33A10Low/- cells and the mammary
fibroblasts showed a number of similarities, for instance cell
adhesion, proteolysis and peptidolysis, which is consistent
with the presence of nonepithelial cells in all three populations.
However, the Sca-1- 33A10Low/- cells also had a distinct func-
tional speciality involving genes encoding proteins that are
associated with smooth muscle contraction. This was consist-
ent with this population containing myoepithelial cells.
33A10High luminal epithelial cells are cognate with 
CD24High Sca-1- luminal epithelial cells
The data suggested that both the Sca-1- 33A10Low/- and Sca-
1+ 33A10Low/- populations were a mixture of epithelial and non-
epithelial cell types, whereas the Sca-1- 33A10High population
was a relatively pure population of Esr1- and Prlr- luminal epi-
thelial cells. Only a few genes were found to be upregulated in
this population compared with the reference, and only at mod-
est levels, probably as a consequence of the reference popu-
lation used being itself mainly composed of Sca-1- 33A10High
cells. Nevertheless, the genes that were upregulated (for
example, that encoding lactotransferrin) or downregulated (for
example, Prlr) were consistent with the Sca-1-/33A10High cells
being cognate with the CD24High Sca-1- Prominin-1- Esr1-
mouse mammary luminal epithelial cells that we recently iden-
tified [14]. This contrasted with previous observations that
33A10 stained all mouse luminal epithelial cells [15,17,18].
To confirm the identity of the Sca-1- 33A10High cells, freshly
isolated mouse mammary cell preparations were stained with
α-CD24, α-Sca-1 and 33A10, and analyzed by flow cytome-
try. The results (Figure 2a) demonstrated that CD24Low Sca-1-
basal/myoepithelial mouse mammary cells were 33A10- and
that CD24High Sca-1- (Esr1-) luminal cells were 33A10High. The
data also demonstrated that CD24High Sca-1+ (Esr1+) luminal
cells did in fact stain with 33A10 but to a lesser extent than the
CD24High Sca-1- (Esr1-) population, forming a distinct
33A10Low population. This confirmed 33A10 as a marker of all
mouse mammary luminal epithelial cells, but it also showed
quantitative differences in staining on different luminal epithe-
lial populations. It also confirmed and extended our previous
findings that Esr1+ and Esr1- luminal epithelial cells of the
mouse mammary gland are distinct epithelial populations.
Rgs2 is highly expressed in the basal/myoepithelial cells 
of the mammary gland
The gene expression data was next interrogated for genes sig-
nificantly differentially regulated within the cell populations
identified by 33A10 and α-Sca-1 co-staining. We noted that
Rgs2, which encodes a small GTPase-activating protein
(GAP) that is involved in the negative regulation of signalling
from G proteins, in particular Gαq, was significantly downreg-
ulated in the Sca-1+ 33A10Low/- and Sca-1- 33A10High popula-
tions, as well as in fibroblasts. However, it was highly
expressed in Sca-1- 33A10Low/- cells. As the latter population
consisted of both CD24Low basal/myoepithelial cells and non-
epithelial cells, but Rgs2 was under-expressed in the fibrob-
lasts, we reasoned that it must be strongly expressed
specifically in the basal/myoepithelial population. To test this,
mouse mammary CD24Low Sca-1- basal/myoepithelial cells,
CD24High Sca-1- (Esr1-) luminal epithelial cells and CD24High
Sca-1+ (Esr1+) luminal cells [14] were freshly isolated and
qPCR analysis of the levels of Rgs2 mRNA was carried out,
using mouse mammary fibroblasts as a comparator. The
results (Figure 2b) confirmed that Rgs2 mRNA expression
was strongly upregulated in basal/myoepithelial cells com-
pared with the fibroblast comparator population and both lumi-
nal epithelial populations. However, Rgs2 expression could
still be detected in the luminal epithelial populations.
To determine whether the RGS2 expression pattern in human
cells was similar to that of the mouse, we analysed gene
expression data from three different microarray platforms
(Affymetrix, Agilent and Codelink), comparing pooled RNA
from primary normal human myoepithelial and luminal epithelial
cells (RNA isolated from 10 different preparations in each
pool) [29]. The results did not show significant differences
between RGS2 expression in normal human myoepithelial and
luminal cells.
Because this result disagreed with the mouse expression data,
we used qPCR to better quantify RGS2 expression levels in
pooled human normal primary myoepithelial and luminal epi-
thelial cells [29]. Human breast fibroblasts [32] were used as
a comparator. This analysis (Figure 2c) demonstrated that, as
with the mouse expression data, RGS2 expression could be
detected in both myoepithelial and luminal epithelial
populations. However, although qPCR showed that RGS2
expression levels were also significantly higher in the human
myoepithelial cells compared with the human luminal cells, the
differences were modest compared with those observed with
the mouse cells. These modest differences could apparently
not be detected by the array platforms. These data did confirm,
however, that the pattern of RGS2 expression in human and
mouse mammary epithelial cells was similar.
RGS2 is a regulator of oxytocin receptor signalling
RGS2 is a GAP that switches off G-protein activity (particu-
larly Gαq activity) and therefore acts as a negative regulator ofPage 7 of 16
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Rgs2 is highly expressed in CD24Low Sca-1- 33A10- mouse mammary basal/myoepithelial and human breast myoepithelial cellsi l  x ressed in CD24Low Sca-1- 3 A10- mouse mam ary basal/myoepithelial nd human breast myoepithelial cells. (a) Flow cytometric 
staining profile of mouse mammary cell preparations stained with anti-Sca-1 and anti-CD24 antibodies together with either a nonspecific rat IgG and 
anti-rat-FITC or 33A10 and anti-rat FITC. The nonspecific IgG and 33A10 staining profiles of the CD24Low Sca-1- basal/myoepithelial cells (33A10-), 
CD24High Sca-1- (Esr1-) luminal cells (33A10High) and CD24High Sca-1+ (Esr1+) luminal cells (33A10Low) [14] are indicated. (b) Mean fold differences ± 
95% confidence limits in RNA abundance for the Rgs2 gene in CD24Low Sca-1- basal/myoepithelial, CD24High Sca-1- (Esr1-) luminal epithelial and 
CD24High Sca-1+ (Esr1+) luminal epithelial mouse mammary cells (n = 3 for all samples) [14]. The dotted lines indicate the 95% confidence limits of the 
comparator sample. All samples show a significant difference to the comparator (**P < 0.01). The basal myoepithelial cells also have a significantly 
higher level of Rgs2 expression than either of the two luminal populations. (c) Mean fold differences ± 95% confidence limits in expression levels for the 
RGS2 gene in myoepithelial and luminal epithelial human breast cells compared with human breast fibroblasts (comparator). See Materials and meth-
ods for details of the samples. The dotted lines indicate the 95% confidence limits of the comparator sample. Both samples show a significant differ-
ence to the comparator (**P < 0.01) and the myoepithelial cells have a significantly higher level of RGS2 expression than the luminal cells.Page 8 of 16
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in the breast, candidate GPCR pathways that might be regu-
lated by RGS2 were examined. One good candidate was the
oxytocin receptor pathway. The oxytocin receptor is a GPCR
related to the vasopressin receptor, which signals through
both Gαq and Gαi subunits [36], and in the breast it is specif-
ically located in the myoepithelium, the same compartment
that is enriched for RGS2 expression.
To test whether RGS2 was a regulator of oxytocin signalling,
the effects of RGS2 over-expression were examined in
Hs578T cells, which have an endogenous, functional oxytocin
receptor [34]. We established a pair of cell lines, one of which
stably expressed the empty parental vector (Hs578T-pcDNA)
whereas the other stably expressed RGS2 (Hs578T-RGS2).
qPCR analysis confirmed that the Hs578T-RGS2 line had
fivefold RGS2 over-expression compared with the control cell
line (Figure 3a).
Intracellular signalling downstream from the oxytocin receptor
is mediated both by calcium signalling [39] and via p44/42
MAPK [36,40]. To determine whether RGS2-regulated cal-
cium signalling downstream of oxytocin receptor activation, a
calcium flux assay was carried out on the Hs578T-pcDNA and
Hs578T-RGS2 cells. The results (Figure 3b) showed that the
calcium flux in these cells following oxytocin stimulation was
identical, indicating that RGS2 does not regulate this pathway.
Next, p44/42 MAPK phosphorylation in response to oxytocin
stimulation in the cell lines was examined. Cells were serum
starved and insulin starved for 2 hours, stimulated with 5 × 10-
7 mol/l oxytocin and then harvested at different time points for
assessment of levels of phosphorylated, active p44/42 MAPK
(Figure 3c,d). In two independent experiments, RGS2 over-
expression significantly (P < 0.001 in both experiments)
reduced p44/42 MAPK phosphorylation after oxytocin
stimulation.
To confirm this result, we examined the effects on p44/42
MAPK phosphorylation of silencing endogenous RGS2 in
wild-type Hs578T cells. Cells transfected with either a control
(siCON) siRNA or an siRNA targeting RGS2 (siRGS2) were
serum and insulin starved and then treated with 1 × 10-7 mol/
l oxytocin. A lower concentration of oxytocin was used to give
a reduced stimulation, which could be measurably altered by
RGS2 silencing. Again, cells were harvested at different time
points and assayed for levels of phospho-p44/42 MAPK. In
two independent experiments, silencing of endogenous RGS2
in wild-type Hs578T cells caused a significant (P < 0.001)
increase in p44/42 MAPK phosphorylation following oxytocin
stimulation (Figure 4a,b). Efficient silencing of endogenous
RGS2 was confirmed by qPCR (Figure 4c).
RGS2 is over-expressed in the majority of breast cancers
Finally, we examined the pattern of expression of RGS2 in
human breast cancer. A data mining approach was first used
to examine RGS2 expression in a set of gene expression data
from normal breast samples (10 pooled isolates of freshly sep-
arated normal luminal cells) and breast cancers (15 freshly iso-
lated infiltrating ductal carcinomas of grade 2 or 3, from which
cells expressing the desmosplastic fibroblast antigen F19 had
been removed) analyzed by four different gene expression
microarray platforms and massively parallel signature
sequencing [29]. The data from all four microarray platforms
showed that RGS2 was significantly upregulated in malignant
breast cancers compared with normal luminal cells (Affymetrix:
3.2-fold increase, P = 3.77 × 10-10; Agilent: 2.49-fold increase,
P = 1.25 × 10-6; CodeLink: 3.02-fold increase, P = 2.14 × 10-
10; brk IMAGE: 2.71-fold increase, P = 1.35 × 10-6). The mas-
sively parallel signature sequencing analysis quantified the
tumour pool as having 96 RGS2 transcripts per million and the
normal luminal pool as having 0 transcripts per million (the
gene was not detected in two independent sequencing runs).
We next compared expression of RGS2 in the tumour pool
with the pooled normal human myoepithelial cells on the
Affymetrix, Agilent and Codelink platforms. These data
showed that the RGS2 expression was also significantly
upregulated in the tumour pool compared with the normal
myoepithelial pool (Affymetrix: 3.48-fold increase, P = 2.23 ×
10-10; Agilent: 2.85-fold increase, P = 4.71 × 10-5; CodeLink:
12.9-fold increase, P = 1.14 × 10-4).
To validate these findings, a panel of samples including normal
breast cells, breast cancer cell lines (including ESR1+ cell
lines, estrogen nonresponsive cell lines, ERBB2 over-express-
ing cell lines and 55 primary tumour samples, some of which
had been depleted of F19-expressing fibroblasts) were ana-
lysed by semi-quantitative RT-PCR for RGS2 expression. The
samples were also analysed for OXTR expression levels. The
results (Figure 5a) confirmed the in silico analysis, with RGS2
expression seen in the majority of samples, being particularly
strong in the solid tumour and F19-depleted samples. In con-
trast, OXTR expression in cell lines and primary tumours was
variable, with only two out of four ESR1+ breast cancer cell
lines, one of three ERBB2 over-expressing cell lines, one basal
origin tumour cell line, eight out of 17 (47%) estrogen nonre-
sponsive cell lines, and 23 out of 56 (41%) primary tumours
having detectable oxytocin receptor gene expression.
For more accurate quantitation of levels of RGS2 mRNA
expression in cell lines and primary tumours, a selection of cell
lines, solid tumours and F19-depleted tumours was examined
by qPCR. The results (Figure 5b) showed that compared with
normal primary cells (either myoepithelial or luminal epithelial
cells, breast fibroblasts, or endothelial cells) most cell lines
had a much reduced level of RGS2 expression. One exception
was the 1089M immortalized normal myoepithelial cell line,
which had high levels of RGS2 expression. However, RGS2
expression was significantly increased in the solid tumours
compared with the normal primary cells. It was increased stillPage 9 of 16
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RGS2 overexpression attenuates oxytocin receptor signalling to p44/42 MAPKi lli  t  /  . (a) quantitative real-time PCR analysis of RGS2 gene expression in 
triplicate samples of stably transfected Hs578T-pcDNA (parental vector) compared with Hs578T-RGS2 cells. Mean expression levels ± 95% confi-
dence limits are shown. Significant differences are indicated (**P < 0.01). RGS2 was fivefold overexpressed in the Hs578T-RGS2 cells compared 
with the control cell line. (b) Analysis of calcium flux in Hs578T-pcDNA and Hs578T-RGS2 cells stimulated with 5 × 10-7 mol/l oxytocin. Both cell 
lines showed an identical response to the stimulus. (c) Time course analysis of p44/42 mitogen-activated protein kinase (MAPK) phosphorylation in 
Hs578T-pcDNA and Hs578T-RGS2 cells stimulated with 5 × 10-7 mol/l oxytocin. (d) Quantitation of phosphorylation analysis. p44/42 MAPK phos-
phorylation was significantly reduced (P < 0.001) in the Hs578T-RGS2 cell line compared with the control Hs578T-pcDNA cells.Page 10 of 16
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ples (including the 1089M cell line), some of which had levels
of RGS2 expression 1,000-fold or more times that of the com-
parator. This suggests that RGS2 mRNA expression is
strongly upregulated specifically in the epithelial cells of the
majority of primary breast cancers.
Discussion
In our previous studies, we found that the mouse mammary
epithelium could be separated into total luminal or myoepithe-
lial fractions by using the 33A10 and JB6 antibodies respec-
tively [17,18], and, more recently, that anti-CD24 staining
identifies three distinct mammary cell populations, namely
CD24- nonepithelial cells, CD24Low basal/myoepithelial cells
and CD24High total luminal epithelial cells [12]. The CD24High
total luminal fraction could be further subdivided into Sca-1+
Prominin+ Esr1+ and Sca-1- Prominin-1- Esr1- fractions [14]. In
the present study we expected that, because the mouse mam-
mary luminal fraction can be isolated with both 33A10 and
anti-CD24 staining, both the CD24High Sca-1+ and CD24High
Sca-1- cells would have identical 33A10 staining patterns.
Instead, we found that the 33A10 antibody differentially
stained the luminal epithelial populations. We were able
initially to identify the Sca-1- 33A10High population as being
identical to CD24High Sca-1- cells on the basis of patterns of
gene expression. Subsequent flow cytometric analysis con-
firmed that 33A10 staining differentiated between the two
luminal epithelial populations we previously identified [14].
CD24High Sca-1- (Esr1-) luminal epithelial cells had a
33A10High staining pattern whereas CD24High Sca-1+ (Esr1+)
Figure 4
Silencing of endogenous RGS2 enhances oxytocin receptor signalling via p44/42 MAPK in Hs578T cells. (a) Hs578T cells transfected with either 
a scrambled control small interfering (si)RNA (SiCON) or an siRNA targeting RGS2 (siRGS) were serum and insulin starved for 2 hours then stimu-
lated with 1 × 10-7 mol/l oxytocin. Cells were harvested at timepoints up to 120 minutes after oxytocin addition and lysates analysed for levels of 
phospho- and total p44/42 mitogen-activated protein kinase (MAPK) by immunoblotting. (b) Quantitation of siRNA knockdown from two independ-
ent transfections. The upper plot is the quantitation of the blots shown in panel a. siRGS2 caused a significant (P < 0.001) increase in phosphoryla-
tion in response to oxytocin. (c) Quantitative real-time PCR analysis of RGS2 expression in Hs578T cells transfected with the siRGS2. Each bar 
represents the mean ± 95% confidence limits of the fold difference in expression compared with the mean expression in the siCON transfected 
cells. Data from four samples harvested from two independent transfections is shown (one of which was also used in the lower oxytocin response 
experiment shown in panel b). Significant differences are indicated (**P < 0.01).Page 11 of 16
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RGS2 is expressed in human myoepithelial and luminal cells and in breast cancers. (a) RNA isolated from normal primary breast cells, normal and 
breast cancer cell lines and primary breast cancers was analysed by semi-quantitative RT-PCR for expression at the transcriptional level of RGS2, 
OXR and a housekeeping gene B2M. (b) Quantitative real-time PCR analysis of RGS2 expression levels in a selection of primary human cells, 
human breast cancer cell lines, solid breast cancers and F19-depleted cancers. Data are mean relative expression levels ± 95% confidence limits (n 
= 3 analyses of each sample). For comparison, the primary myoepithelial and primary luminal cell data from Figure 2c have been included on this 
graph. Note that the y-axis is a log10 scale.Page 12 of 16
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/9/6/R85luminal epithelial cells were 33A10Low. As expected, CD24Low
Sca-1- basal/myoepithelial cells were 33A10-. This new differ-
ential staining pattern of the 33A10 antibody was most likely
observed because of advances in flow cytometry technology
and analysis software since our early observations, although
mouse strain differences in the pattern of expression of the
antigen recognized by the 33A10 antibody (most likely a milk
fat globule membrane antigen) [15,16] cannot be excluded.
With these data, we were able to extend our analysis of the
mouse mammary epithelium, confirming that there are two dis-
tinct populations of luminal epithelial cells [14]. Furthermore,
we used the gene expression array data that formed the basis
for defining the identity of the Sca-1- 33A10High population to
identify Rgs2 as a gene highly differentially regulated between
the epithelial populations of the mammary gland. Remarkably,
RGS2 is over-expressed in the majority of breast cancer cell
lines and primary breast tumours. RGS2 and the pathways it
regulates are therefore important new candidate therapeutic
targets for the treatment of breast cancer.
RGS2 is a regulator of GPCRs, which acts as a GTPase-acti-
vating protein (GAP), primarily (although not exclusively)
downregulating signalling from the Gαq subunit [41]. GPCRs
are the largest family of cell-surface molecules involved in sig-
nal transduction [42]. They all have a core of seven
transmembrane α-helices and, after agonist binding, interact
with the αβγ G-protein heterotrimers. This catalyzes the disso-
ciation of Gα-bound GDP and its replacement with GTP, lead-
ing to dissociation of the Gβγ from the Gα subunits. The Gα•
GTP and Gβγ subunit complexes then both stimulate down-
stream effectors until the GTP is hydrolyzed back to GDP and
the signal switched off [42]. GTP hydrolysis is regulated by the
RGS proteins, which act as GAPs for Gα subunits, although
they can also have GAP-independent regulatory functions
[43].
The diverse signalling roles of GPCRs in cancer were recently
reviewed [42]. In breast cancer, these include potential roles
in growth, metastasis, angiogenesis and hormone therapy
resistance. Given this diversity, determination of the specific
function(s) of RGS2 in the context of the breast and breast
cancer is extremely difficult. Rgs2 knockout mice were viable
and had normal reproduction, although mammary phenotypes
and lactation were not examined [41,44]. The mice did, how-
ever, exhibit a hypertensive phenotype, with renovascular
abnormalities, persistent constriction of resistance vasculature
and prolonged response of vasculature to vasoconstrictors.
These effects were mediated through angiotensin II signalling
and α1-adrenergic receptors and the hypertensive phenotype
could be blocked with AT1 receptor antagonists [41]. Analysis
of the mice also demonstrated that Rgs2 plays role in T-cell
activation, synapse development in hippocampus and emotive
behaviours [44]. The involvement of the gene in mediating vas-
cular constriction and its strong over-expression in the basal
mammary cell compartment suggested that at least one role
for RGS2 in the breast is as a regulator of oxytocin signalling
in the mammary gland, regulating myoepithelial cell contrac-
tion during lactation. Indeed, the data presented here confirm
that RGS2 modulates signalling of the oxytocin receptor to
p44/42 MAPK but not oxytocin receptor-mediated calcium
signalling, suggesting that it does indeed regulate signalling of
this receptor in the myoepithelial cells.
Remarkably, RGS2 gene expression was also upregulated in
the majority of breast cancers examined, suggesting that dys-
function in the pathway or pathways regulated by RGS2 in the
breast is an obligate event in breast cancer development.
RGS2 and OXTR expression levels were not correlated in
breast cancer, suggesting that RGS2 modulates a different
GPCR pathway(s) in breast tumours. Exactly which pathway
remains unclear. A number of GPCRs have been previously
reported to be overexpressed in breast cancer, including
CCR1, Opsin-3, CXCR4, PAR1, PAR2, EP2, EP4, GPR30
and the C3A anaphylatoxin chemotactic receptor [42,45],
although whether any of these are regulated by RGS2 remains
unknown. One clue to the pathways involved may be that
RGS2 was upregulated in the solid breast cancers, and in par-
ticular in the F19-depleted cancers, but tended to be less
strongly expressed in cancer cell lines than in the normal tis-
sue. This suggests that RGS2 expression in tumours is a con-
sequence of interactions with the tumour microenvironment.
Identification of the GPCR pathway(s) regulated by RGS2 in
breast cancer will be key to assessing whether it has a critical
function in cancer biology and whether this pathway is of value
as a therapeutic target. GPCRs can have tumour suppressor
activity, as has been noted for GPR54 and metastasis in
breast cancer [42], and tumour development would lead to
selective pressure to block such pathways. Mechanisms for
blocking the activity of tumour suppressor GPCR pathways
could include upregulation of negative regulators of GPCRs,
such as RGS2. Alternatively, GPCRs can provide cellular pro-
liferation and survival signals [42,46,47], possibly in response
to interactions with the tumour microenvironment, and RGS2
upregulation may be the result of a negative feedback mecha-
nism. This would be consistent with its high expression in in
situ cancers (Figure 5b). In this case, alternative survival sig-
nals might be selected for in tumour development to bypass
the RGS2 block. Identifying and blocking alternative survival
signals may enable a 'synthetic lethality' approach [48] to
treating breast cancers with high levels of RGS2. Such an
approach is attractive because direct targeting of RGS2 itself
may prove problematic because of possible side effects result-
ing from its role in the regulation of vasoconstriction. However,
the very large difference in RGS2 expression between F19-
depleted tumours and normal endothelial cells (Figure 5b)
suggests that a pronounced therapeutic window for RGS2
targeting exists.Page 13 of 16
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[49], and so it is perhaps counterintuitive that RGS2, which
suppresses p44/42 MAPK phosphorylation in oxytocin signal-
ling, is highly expressed in breast cancers and cancer cell
lines. However, RGS2 acts at the level of the G protein in the
signalling pathway, not on p44/42 MAPK itself. RGS2 could
suppress GPCR signalling even if p44/42 MAPK is activated
via alternative routes. Furthermore, intracellular signalling is
compartmentalized by spatial restriction mechanisms such as
immobilization in lipid rafts [50,51] or attachment to scaffold
proteins [52,53], and RGS2 could block phosphorylation of
the GPCR signalling-associated p44/42 MAPK pool without
affecting other pools. Thus p44/42 MAPK activity could be
high in a tumour, even if the GPCR-associated activity is low.
Conclusion
We have confirmed and extended our previous analyses of
prospectively isolated mouse mammary epithelial subpopula-
tions by demonstrating that different levels of 33A10 antibody
staining identify different luminal epithelial subpopulations.
Furthermore, molecular analysis of prospectively isolated
mammary epithelial cells has identified Rgs2 as a modulator of
oxytocin receptor signalling that is expressed most strongly in
the myoepithelial cell layer. The RGS2 gene, but not the OXTR
gene, was also shown to be over-expressed in the majority of
breast cancers, identifying the product of this gene, or the
pathway(s) it regulates, as potentially significant therapeutic
targets. However, because the function of RGS2 is unlikely to
be mediated through oxytocin receptor signalling in breast
cancer, its role in the pathogenesis of the disease remains to
be elucidated.
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